Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13359MR)

This product GTTS-WQ13359MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13359MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14670MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ12280MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ10298MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ15228MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ4447MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ2307MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ2134MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ8665MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW